Risk of venous thromboembolism in Covid-19 outpatients found to be low
A recent study exploring the risk of venous thromboembolism (VTE) in non-hospitalised Covid-19 patients has found that their absolute risk…
20 Mar 2023
Race for a first-to-market therapy for NASH heats up
The race for a first-to-market therapy in non-alcoholic steatohepatitis (NASH) has been a marathon, with many companies facing numerous setbacks and failures. However, it appears that two companies have gained…
16 Mar 2023
Which biotechs need to find a new bank after the collapse of Silicon Valley Bank?
Silicon Valley Bank (SVB), the 16th largest bank in the US, collapsed on Friday 10 March. Its operations were seized by the Federal Deposit Insurance Corporation after a nearly two-day…
15 Mar 2023
HSBC acquires SVB UK in strategic move to expand presence in biotech sector
The multinational bank HSBC’s acquisition of Silicon Valley Bank UK was praised as the UK Government and Bank of England moved quickly to secure the deal over the weekend. The…
08 Mar 2023
Eli Lilly places price cap of $35 on out-of-pocket insulin cost
Eli Lilly has announced that it will reduce the price of its most commonly used insulin, Humalog, in the US, by 70% and cap the out-of-pocket cost for those on…
07 Mar 2023
CNM-Au8 could address vision problems in multiple sclerosis
Clene has presented updated trial results for its Visionary MS Phase II clinical trial for its lead pipeline candidate, CNM-Au8. The trial is investigating CNM-Au8 as a treatment for patients…
06 Mar 2023
Tuoyi to transform treatment of recurrent/metastatic nasopharyngeal carcinoma
Patients in the US and EU with recurrent or metastatic nasopharyngeal carcinoma (NPC), a subtype of head and neck squamous cell carcinoma (HNSCC), are mostly treated with a combination of…